Treatment of brucellosis in a young child with trimethoprim/sulfamethoxazole anaphylaxis  by Teker, Demet et al.
JS
T
w
a
D
T
a
o
b
P
c
P
R
T
h
1ournal of Infection and Public Health (2014) 7, 553—556
HORT REPORT
reatment  of  brucellosis  in  a  young  child
ith  trimethoprim/sulfamethoxazole
naphylaxis
emet  Tekera,  Gonul  Tanirb,  Serap  Ozmenc,
urkan  Aydın  Tekeb,∗,  Sennur  Kelesc,  Ilknur  Bostancı c
Dr.  Sami  Ulus  Maternity  and  Children’s  Training  and  Research  Hospital,  Department
f Pediatrics,  Turkey
Dr.  Sami  Ulus  Maternity  and  Children’s  Training  and  Research  Hospital,  Division  of
ediatric Infectious  Diseases,  Turkey
Dr.  Sami  Ulus  Maternity  and  Children’s  Training  and  Research  Hospital,  Division  of
ediatric Allergy  and  Immunology,  Turkey
eceived  19  June  2014;  accepted  11  July  2014
KEYWORDS
Brucellosis;
Children;
Trimethoprim/
sulfamethoxazole;
Anaphylaxis
Summary  Brucellosis  is  a  common  zoonotic  disease  throughout  the  world.  Brucella
spp.  transmit  to  humans  through  contact  with  ﬂuids  of  infected  animals,  especially
sheep,  cattle,  and  goats.  It  is  also  transmitted  by  ingestion  of  ﬂuid-derived  products
of  infected  animals,  such  as  unpasteurized  milk  and  cheese.  Brucella  spp.  changes  pH
level  of  intracellular  environment,  so  the  ﬁrst  treatment  approach  is  to  administer
antibiotics  that  have  activity  in  acidic  conditions.  Anti-brucellosis  treatment  regi-
mens  include  doxycycline  for  children  older  than  eight  years  old  and  rifampicin  and
trimethoprim/sulfamethoxazole  (TMP-SMX)  combination  therapy  for  children  under
eight  years  old,  which  may  be  able  to  act  intracellularly  under  acidic  conditions.  A
TMP-SMX  allergy  causing  anaphylaxis  has  been  reported  previously.  No  alternative
anti-brucellosis  treatments  have  been  reported  in  the  literature  for  patients  under
eight  years  old  with  a  TMP-SMX  allergy.  Here,  we  report  a  case  of  a  child  with  brucel-
losis  and  a  TMP-SMX  allergy  who  was  under  eight  years  old  at  the  time  of  diagnosis
and  was  successfully  treated  with  rifampicin,  ciproﬂoxacin,  and  gentamicin.
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Introduction
Brucellosis  is  a  common  zoonotic  disease
throughout  the  world.  Treatment  options  for
childhood  brucellosis  are  limited.  A  trimetho-
prim/sulfamethoxazole  (TMP-SMX)  allergy  causing
anaphylaxis  has  been  reported  [1,2]  previously.
However, an  alternative  anti-brucellosis  treatment
for children  under  the  age  of  eight  with  a  TMP-SMX
allergy has  not  been  reported  in  the  literature.
Here, we  present  a  case  of  a  child  under  eight
years of  age  with  brucellosis  and  a  TMP-SMX  allergy
who was  successfully  treated  with  rifampicin,
ciproﬂoxacin,  and  gentamicin.
Case report
A  previously  healthy  2.5-year-old  girl  had  been
admitted to  a  hospital  with  a  high-grade  fever
(39.5 ◦C).  She  had  a  history  of  consumption  of
unpasteurized cheese  and  a  family  history  of
brucellosis.  A  diagnosis  of  brucellosis  was  con-
ﬁrmed  by  a  positive  serum  agglutination  test  (SAT)
and Coombs  test  at  a  titer  of  1/160.  Thereafter
gentamicin (5  mg/kg/day,  twice  daily  i.v)  plus
TMP-SMX  (10  mg/kg/day,  twice  daily  p.o)  was  pre-
scribed to  the  patient.  Because  of  the  occurrence
of a  generalized  rash  10  h  after  the  last  TMP-SMX
dose on  the  13th  day  of  treatment,  the  patient  was
referred  to  our  hospital.  A  physical  examination
at admission  revealed  a  maculopapular  skin  rash
on her  cheeks,  upper  arms  and  legs  (Fig.  1).
The results  of  laboratory  investigations  were  as
follows:  hemoglobin  12.6  mg/dL,  white  blood  cell
count (WBC)  7100/mm3, platelets  253,000/mm3,
aspartate aminotransferase  165  U/L  (normal
<48 U/L),  alanine  aminotransferase  167  U/L  (nor-
mal <48  U/L),  and  total  immunoglobulin  (Ig)  E
23.4 IU/mL  (normal  range  0—5  IU/mL).  Serologi-
cal tests  for  hepatitis  A  virus,  hepatitis  B  virus,
hepatitis C  virus,  human  immunodeﬁciency  virus,
Epstein—Barr  virus  and  cytomegalovirus  were
negative. Tests  for  Brucella  ELISA  IgG  and  IgM  were
positive.  A  serum  agglutination  test  and  Coombs
test were  positive  at  titers  of  1/800  and  1/640,
respectively. A  blood  culture  yielded  Brucella  spp.
We consulted  with  the  pediatric  allergy  clinic  to
determine  whether  TMP-SMX  could  be  used  for
her treatment.  Because  the  patient’s  skin  prick
test for  TMP-SMX  was  negative,  the  application
of a  challenge  with  10  mg/kg/day  TMP-SMX  was
performed.  Although  the  patient  did  not  display
symptoms of  an  allergic  reaction  immediately  after
the ﬁrst  TMP-SMX  dose  of  5 mg/kg,  3.5  h  later,  the
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atient  experienced  restlessness,  a generalized
aculopapular  rash,  uvular  edema  and  signiﬁcant
achycardia  (pulse  rate  200/min).  After  adrenaline,
rednisolone  and  H1-antihistamine  injections,  the
atient was  clinically  stabilized.  The  patient  was
iagnosed  as  having  experienced  TMP-SMX  ana-
hylaxis,  and  the  patient’s  family  was  informed  of
his diagnosis  and  the  desensitization  protocol  for
MP-SMX.  Her  family  rejected  the  desensitization
rotocol; therefore,  we  searched  for  alternative
reatment protocols.  Rifampicin  (20  mg/kg/day),
iproﬂoxacin (20  mg/kg/day),  and  gentamicin  (for
he ﬁrst  ﬁve  days)  were  prescribed  to  the  patient
s an  alternative  treatment.  On  the  5th  day  of  the
reatment  regimen,  she  became  asymptomatic,
nd on  the  10th  day  of  the  treatment,  a  blood
ulture was  negative  for  Brucella  spp.  She  was
ischarged  with  a good  clinical  condition  and
as followed  as  an  outpatient  for  and  relapses
r recurrences  of  brucellosis.  Her  blood  culture,
AT, Brucella  ELISA  IgM,  IgG  and  Coombs  test
esults were  negative.  The  treatment  regimen  of
ifampicin  and  ciproﬂoxacin  was  stopped  after  six
eeks.
iscussion
rucellosis  is  a  major  public  health  problem  in
urkey.  Risk  factors  that  have  been  reported  for  654
63.6%)  of  1028  Turkish  brucellosis  patients  include
 history  of  consumption  of  raw  milk  and  dairy
roducts. Brucellosis  has  a  wide  clinical  spectrum,
rom  asymptomatic  cases  who  were  diagnosed  dur-
ng family  screening  life-threatening  cases.  A  family
istory of  brucellosis  has  been  reported  for  17.8%
f brucellosis  cases  in  Turkey  [3].  The  present  case
ad a history  of  a  three-day  fever,  but  the  patient’s
pidemiological  history  was  strong  in  regard  to
rucellosis.  In  the  present  case,  the  diagnosis  of
rucellosis  was  conﬁrmed  both  bacteriologically
nd serologically.
Brucella  spp.  are  intracellular  pathogens  that
eside and  proliferate  in  Brucella  containing  vac-
oles in  phagocytic  cells;  thus,  they  avoid  immune
ystem  recognition.  The  optimal  antimicrobial
reatment for  brucellosis  includes  agents  that
ct intracellularly  and  have  a low  risk  of  gen-
rating Brucella  resistance  in  order  to  prevent
elapses. For  this  reason,  combination  treatment
egimens that  include  TMP-SMX,  doxycycline  and
ifampicin  are  recommended  for  brucellosis.  There
re two  effective  traditional  treatment  regimens
or different  age  groups:  for  children  over  8  years
ld, oral  doxycycline  (4  mg/kg/day)  and  rifampicin
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CFigure  1  Maculopapul
20  mg/kg/day)  are  typically  prescribed,  and  for
hildren under  8  years  old,  oral  co-trimoxazole
8 mg/kg/day),  trimethoprim  (40  mg/kg/day)  and
ifampicin (20  mg/kg/day)  are  typically  prescribed.
oth are  prescribed  for  6  weeks  [4].
The present  2.5-year-old  brucellosis  patient  had
 TMP-SMX  allergy.  To  our  knowledge,  no  alterna-
ive anti-brucellosis  therapy  for  the  children  under
ight years  old  has  been  reported  in  the  English
iterature. Tigecyclin,  meropenem,  liposome-
ncapsulated aminoglycoside,  azithromycin  and
entamicin  have  been  reported  as  alternative
rugs for  the  treatment  of  brucellosis  in  adults  and
hildren  over  8  years  old  [5—8].  It  is  well  known
hat brucellosis  treatment  with  a  single  agent
r treatment  for  less  than  4—6  weeks  can  result
n relapses  and  complications  [9]. Relapses  are
dentiﬁed  by  a  new  positive  blood  culture  or  the
ppearance of  signs  or  symptoms  of  brucellosis.
he rate  of  relapse  following  treatment  is  approx-
mately 5—15%  with  the  traditional  treatment
egimen [10].
It  has  been  reported  that  ciproﬂoxacin  may
e useful  for  brucellosis  cases  of  drug  resistance,
ntimicrobial  toxicity  and  relapse.  These  studies
howed  that  although  ciproﬂoxacin  is  not  the  ﬁrst
hoice  for  brucellosis  treatment,  due  to  its  good
n vitro  activity,  it  can  be  used  in  combination
ith rifampicin  [10,11]. According  to  the  literature,
Fin  rash  of  the  patient.
ollow-up  visits  take  place  each  month  during  the
rst three  months  after  the  initiation  of  brucel-
osis treatment.  In  this  case,  after  the  ﬁrst  three
onths, follow-up  visits  also  took  place  every  three
onths  for  the  rest  of  the  ﬁrst  year  after  the  ini-
iation of  treatment.  In  this  case,  the  clinical  and
erological  ﬁndings  at  the  follow-up  visits  were  neg-
tive. According  to  the  reported  treatment  success
riteria,  the  ciproﬂoxacin  +  rifampicin  +  gentamicin
egimen  was  successful  in  our  patient  [4].
In conclusion,  alternative  treatment  regimens
or children  under  eight  years  old  with  a TMP-SMX
llergy that  have  been  reported  in  the  literature
re not  sufﬁcient.  Using  the  best  approach  in  such
ases is important  because  unsuccessful  treatment
f brucellosis  can  cause  signiﬁcant  complications
nd the  risk  of  relapse.  Therefore,  it is  necessary
o search  for  alternative  treatments  for  this  patient
opulation  and  to  provide  new  treatment  sugges-
ions.
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